SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as it breaks into new all-time high territory, with the community largely focused on the stock's massive institutional momentum and its role as the centerpiece of the ongoing AI infrastructure supercycle. While many investors are celebrating the breakout and discussing aggressive new price targets, others are debating the sustainability of the rally, noting potential divergences in market breadth and questioning the long-term impact of extreme valuations.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing a severe sell-off following the collapse of a key relationship with Marvell, which terminated purchase orders citing a confidentiality breach by management. The community is sharply divided between investors calling for a total leadership overhaul due to the perceived communication failures and those attempting to justify the drop as an overreaction that creates a long-term buying opportunity.

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. It operates through the following segments: Seed and Integrated Products, Crop Protection, Crop Nutrition, and Emerging Solutions. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

Moolec Science SA is trending due to significant retail interest surrounding its low-float status, which market participants are actively discussing as a primary catalyst for potential short-squeeze activity. The community is sharply divided, with bulls pointing to the company's molecular farming technology as a long-term play, while bears express skepticism regarding its underlying financials and the risk of being left as 'exit liquidity' in what they label a pump-and-dump scheme.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as investors react to successful demonstration flights in New York City and ongoing FAA certification progress, signaling a shift from concept to real-world deployment. While the community is actively debating the stock's long-term execution risk and potential for volatility, many see the recent milestones as a critical step toward the company's 2026 commercial launch goals.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is seeing heightened activity as investors weigh recent reports of revenue growth and operational improvements against ongoing concerns about cash burn and a challenging retail environment. The community remains deeply divided, with some traders focused on potential squeeze setups and the company's long-term turnaround strategy, while others emphasize the stock's significant decline and persistent volatility.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is facing downward pressure as investors react to conservative full-year guidance and concerns surrounding the upcoming transition of its lead product, DefenCath, away from its initial reimbursement status. Despite strong recent revenue and a newly authorized share buyback program, the community remains divided, with long-term holders highlighting the stock's low valuation relative to its pipeline potential and upcoming Phase III trial data for Rezzayo.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing heightened community interest driven by speculation surrounding ecosystem development, token burns, and potential regulatory shifts. Investors are actively discussing staking strategies, the project's long-term recovery potential, and its resilience compared to broader market volatility.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is experiencing significant volatility and trading volume as investors react to bullish institutional accumulation and ongoing speculation regarding potential buyout interest or strategic partnerships for its lead asset, paridiprubart. Community discussions remain polarized between optimistic longs betting on a major acquisition or regulatory breakthrough and vocal skeptics highlighting historical trial delays and the potential for share dilution.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

High-Trend International Group is experiencing extreme volatility and intense community speculation following a parabolic run that has driven significant short-squeeze discussions. Investors are actively debating the sustainability of this momentum, with many highlighting the stock's low float and the ongoing battle between aggressive buying and short-selling interest.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is capturing significant attention as investors react to positive Phase 3 clinical trial results for its acne treatment, which met all primary and secondary endpoints in China. The community is actively discussing the stock's potential for acquisition, noting its valuation disparity compared to recent sector buyouts and its strategic positioning in both the MASH and acne markets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
